Takeda Pharmaceutical Company Ltd. and Shire Biotechnology company took an exciting step forward by completing the acquisition that was announced in 2018 and becoming a global biopharmaceutical company headquartered in Japan.
Takeda, the largest pharmaceutical company in Asia and one of the top 10 largest pharmaceutical companies in the world, now has an expanded geographic footprint and leading positions in Japan and the United States, with the acquisition of the global specialty biopharmaceutical company, Shire, headquartered in the United Kingdom and with an operational base in the United States.
Takeda now has an extended reach, bringing medicines to more than 80 countries and regions worldwide. The combined company enables them to deliver highly-innovative medicines and transformative care to more people around the world than ever before. Their R&D efforts are now focused on four therapeutic areas— Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases, with some specific R&D investment also committed to Plasma-Derived Therapies and Vaccines.
The Alpha-1 Foundation congratulates Takeda in this new venture to enable the delivery of highly-innovative medicines and transformative care to more patients around the world, including the rare disease patient community, such as those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1).
To learn more, please click here.